0000000000160346

AUTHOR

Fabrizio Bronte

showing 45 related works from this author

IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus …

2012

Background. Polymorphisms in the interleukin-28B are important determinants in the spontaneous and drug-induced control of hepatitis C virus infection. Design and Methods. We assessed the association of rs8099917 and rs12979860 polymorphisms with spontaneous viral clearance, severity of liver fibrosis, and response to interferon-monotherapy in 245 Thalassemia Major patients with Hepatitis C Virus infection. Results. Ninety-eight patients (40%) had a spontaneous viral clearance, while 147 patients (60%) developed a chronic infection. Spontaneous viral clearance was more frequent among patients with the T/T genotype of rs8099917 polymorphism (OR 2.130; p=0.008) or C/C genotype of rs12979860 p…

AdultLiver CirrhosisMalethlassemia hepatitis CInterferon InducersAdolescentHepacivirusHepatitis C virusAlpha interferonHepacivirusAdolescent; Adult; Antibodies Viral; Antiviral Agents; Cohort Studies; Female; Follow-Up Studies; Hepacivirus; Hepatitis C Chronic; Humans; Interferon Inducers; Interferon-alpha; Interleukins; Liver Cirrhosis; Male; Polymorphism Single Nucleotide; Prognosis; Viral Load; Young Adult; beta-Thalassemiamedicine.disease_causeAntibodies ViralAntiviral AgentsPolymorphism Single NucleotideCohort StudiesYoung AdultGenotypemedicineHumansInterferon inducerbiologymedicine.diagnostic_testInterleukinsbeta-ThalassemiaInterferon-alphaHematologyHepatitis CHepatitis C ChronicViral Loadbiology.organism_classificationmedicine.diseasePrognosisLiver biopsyImmunologyFemaleInterferonsOriginal Articles and Brief ReportsViral loadFollow-Up Studies
researchProduct

Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: A meta-analysis.

2009

BACKGROUND/AIMS: Efficacy of retreatment with pegylated interferon (PEG-IFN) plus ribavirin of non-responders to standard or pegylated IFN plus ribavirin has been assessed in various studies, but sustained virologic response (SVR) rates are variable and factors influencing efficacy and tolerability still remain incompletely defined. We aimed to focus on SVR rates and to identify factors influencing them in this meta-analysis. METHODS: MEDLINE as well as a manual search were used. Studies were included if they were controlled or uncontrolled trials, if they had been published as full-length papers and if they included non-responders to standard or pegylated IFN and ribavirin therapy. Fourtee…

pegylated interferon ribavirin non-responders hepatitis C
researchProduct

Point‐of‐care HCV RNA testing in the setting of DAA therapy: HCV‐FiS (HEpatitis C Virus Fingerstick Study)

2019

HCV-RNA assessment during therapy with Direct-Acting Antiviral (DAA) regimens still relies on assays requiring blood collection and transport to a specialised laboratory, which may compromise linkage to care. GeneXpert-HCV Viral Load (GXHVL) (Cepheid) is a plasma-based assay used at point of care (POC) with a sensitivity of ≤10 IU/mL, and, results available within 2 hours. Fifty-nine consecutive HCV-patients ready for DAAs treatment were enrolled. HCV-RNA was simultaneously tested using Roche TaqMan RT-PCR (venous blood sample) and GXHVL (capillary blood collected by fingerstick), at baseline (BL), week 4 (W4) of therapy, end of therapy (EOT) and week 12 of follow-up (W12FU). Both assays de…

Malemedicine.medical_specialtyEnd of therapyFingerstickHepatitis C virusHepacivirusmedicine.disease_causeAntiviral AgentsInternal medicineTaqManmedicineOutpatient settingHumansHCV DAAAgedPoint of careHepatologybusiness.industryVenous blood sampleMiddle AgedViral LoadHepatitis CPoint-of-Care TestingRNA ViralFemalebusinessViral loadLiver International
researchProduct

Transient elastography (TE) as a tool to evaluate acute liver damage: A prospective, multicentric cohort study

2008

Pathologymedicine.medical_specialtyHepatologybusiness.industryGastroenterologymedicineLiver damageTransient elastographybusinessCohort studyDigestive and Liver Disease
researchProduct

An Outbreak of Hepatitis C Virus Infection Among Transfused Thalassemia Patients: Root Cause Analysis, Phylogenetic Epidemiology and Antiviral Therapy

2021

Background: Occurrence of HCV infection is reduced by effective risk management procedures, but patient-to-patient transmission continues to be reported in healthcare settings. We report an outbreak of 11 patients with HCV acute hepatitis (seven new infections and four re-infections) among 128 thalassemia patients followed at a Hospital in Sicily. Methods All patients with acute hepatitis and known chronic infection were tested for HCV-RNA, HCV genotyping, and NS3, NS5A and NS5B HCV-genomic regions sequencing.  To identify transmission clusters we built phylogenetic trees for each gene employing Bayesian methods.  Findings All patients with acute hepatitis were infected with HCV genotype 1b…

Ledipasvirmedicine.medical_specialtyBlood transfusionSofosbuvirTransmission (medicine)business.industryHepatitis C virusmedicine.medical_treatmentmedicine.disease_causeHelsinki declarationchemistry.chemical_compoundChronic infectionchemistryInternal medicineEpidemiologymedicinebusinessmedicine.drugSSRN Electronic Journal
researchProduct

Liver disease in chelated transfusion-dependent thalassemics: the role of iron overload and chronic hepatitis C.

2008

Iron overload and hepatitis virus C infection cause liver fibrosis in thalassemics. In a monocentric retrospective analysis of liver disease in a cohort of 191 transfusion-dependent thalassemics, in 126 patients who had undergone liver biopsy (mean age 17.2 years; 58 hepatitis virus C-RNA positive and 68 hepatitis virus C-RNA negative) the liver iron concentration (median 2.4 mg/gr dry liver weight) was closely related to serum ferritin levels (R = 0.58; p<0.0001). Male gender (OR 4.12) and serum hepatitis virus C-RNA positivity (OR 11.04) were independent risk factors for advanced liver fibrosis. The majority of hepatitis virus C-RNA negative patients with low iron load did not develop liv…

AdultLiver CirrhosisMaleLiver Iron ConcentrationCirrhosisIron OverloadAdolescentHepatitis C virusBiopsyHepacivirusSettore MED/08 - Anatomia Patologicamedicine.disease_causeCohort StudiesLiver diseasethalassemic iron chronic hepatitis CMedicineHumansRetrospective StudiesSettore MED/12 - Gastroenterologiamedicine.diagnostic_testbusiness.industryTransfusion ReactionHematologyHepatitis CHepatitis C ChronicViral Loadmedicine.diseaseLiverLiver biopsyImmunologySplenectomyThalassemiaFemalebusinessHepatic fibrosisViral loadHaematologica
researchProduct

HepatomiRNoma: The proposal of a new network of targets for diagnosis, prognosis and therapy in hepatocellular carcinoma

2015

Abstract: The diagnosis and treatment of hepatocellular carcinoma (HCC) underwent a huge advancement in the last years. Recently, microRNAs (miRNAs) have been also studied to provide a new tool for early diagnosis of high risk patients, for prognostic classification to identify those patients who benefit cancer treatment and for predictive definition to select the right targeted drug. In this review we revised all the available data obtained to explore the role of miRNAs in HCC. This analysis led to identification of miRNAs which could gain a diagnostic, prognostic or predictive role. The results of studies on miRNAs involved in HCC are initial and far from providing scientific evidences to…

Serum0301 basic medicineCarcinoma HepatocellularHepatocellular carcinomaPrognosimedicine.medical_treatmentBioinformaticsTargeted therapyTargeted therapy03 medical and health sciences0302 clinical medicinePrognostic classificationBiomarkers TumormedicineHumansProspective cohort studyHigh risk patientsbusiness.industryLiver NeoplasmsMicroRNAHematologyPrognosismedicine.diseaseCancer treatmentClinical PracticeMicroRNAs030104 developmental biologyOncology030220 oncology & carcinogenesisHepatocellular carcinomaHuman medicineDiagnosis; Hepatocellular carcinoma; MicroRNA; Prognosis; Serum; Targeted therapy; Hematology; Oncology; Geriatrics and GerontologyGeriatrics and GerontologybusinessDiagnosiCritical Reviews in Oncology/Hematology
researchProduct

HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals

2017

Anecdotal reports suggest that patients with chronic hepatitis C virus (HCV) hepatitis and overt or occult hepatitis B virus (HBV) coinfection may reactivate HBV when HCV is suppressed or cleared by direct-acting antivirals (DAAs). We assessed the prevalence of overt or previous HBV coinfection and the risk of HBV reactivation in patients with HCV cirrhosis treated with DAAs. This was a retrospective cohort of 104 consecutive patients with HCV cirrhosis treated with DAAs. Serum HCV-RNA and HBV-DNA were tested at weeks 4, 8 and 12 of DAAs therapy and at week 12 of follow-up. At the start of DAAs, eight patients (7.7%) were HBsAg positive/HBeAg negative with undetectable HBV-DNA and low level…

AdultLiver CirrhosisMaleHepatitis B virusHBsAgCirrhosisHepacivirusHepacivirusmedicine.disease_causeAntiviral AgentsVirus03 medical and health sciencesHepatitis B Chronic0302 clinical medicineVirologymedicineHumansHBV-DNA reactivationnucleos(t)ide analogues therapyAgedRetrospective StudiesHepatitisHepatitis B virusHepatologybiologyCoinfectionbusiness.industryvirus diseasesRetrospective cohort studyHepatitis C ChronicMiddle Agedmedicine.diseasebiology.organism_classificationVirologyprevious HBV infectiondigestive system diseasesInfectious DiseasesHBV/HCV coinfection030220 oncology & carcinogenesisDNA ViralCoinfectionRNA ViralFemaleVirus Activation030211 gastroenterology & hepatologysustained virological responsebusiness
researchProduct

Liver stiffness measurement by transient elastography predicts early recovery from acute hepatitis

2010

We read with interest the lead article by Castera and Pinzani,1 particularly the comment regarding the role of transient elastography (TE) in the context of acute hepatitis (AH). The assumption that liver stiffness is determined exclusively by hepatic fibrosis has been challenged by evidence that patients with AH can have high values of liver stiffness measurement (LSM) by TE.2 AH is a suitable model for studying the kinetics of LSM, since inflammation and necrosis increase rapidly and sometimes massively, but may revert with equal speed. We evaluated 92 consecutive patients (mean age 41.8±16.3 years, 71.7% males) with symptomatic AH to assess how LSM was influenced by aetiology, and whethe…

Pathologymedicine.medical_specialtyNecrosisbusiness.industryGastroenterologyEarly recoveryContext (language use)Gastroenterologyliver stiffnessLiver stiffnessInternal medicineAcute Disease; Adult; Elasticity Imaging Techniques; Female; Hepatitis Viral Human; Humans; Male; Middle Aged; PrognosisEtiologymedicinemedicine.symptomTransient elastographyHepatic fibrosisbusinessAcute hepatitis
researchProduct

Insulin resistance is a major determinant of liver stiffness in nondiabetic patients with HCV genotype 1 chronic hepatitis.

2009

BACKGROUND: In patients with chronic hepatitis C (CHC), liver stiffness measurement (LSM) by transient elastography (TE), is closely related to the stage of fibrosis, but may be affected by necroinflammation. Other factors, such as insulin resistance (IR), might influence the performance of LSM. AIMS: To evaluate in a cohort of nondiabetic patients with genotype 1 CHC, whether IR and other anthropometric, biochemical, metabolic and histological factors contribute to LSM and to identify the best cut-off values of LSM for predicting different stages of fibrosis. METHODS: Nondiabetic patients with genotype 1 CHC (n = 156) were evaluated by liver biopsy (Metavir score), anthropometric, biochemi…

AdultLiver CirrhosisMalemedicine.medical_specialtyGenotypemedicine.medical_treatmentHepatitis C virusBiopsySettore MED/08 - Anatomia Patologicamedicine.disease_causeGastroenterologyYoung AdultInsulin resistanceFibrosisRisk FactorsInternal medicinemedicineHumansPharmacology (medical)AgedHepatitisAged 80 and overSettore MED/12 - GastroenterologiaHepatologymedicine.diagnostic_testbusiness.industryInsulinGastroenterologyHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseEndocrinologyLiverLiver biopsyinsulin resistance liver stiffnessElasticity Imaging TechniquesFemaleInsulin ResistanceTransient elastographybusinessAlimentary pharmacologytherapeutics
researchProduct

Noninvasive assessment of liver fibrosis in thalassaemia major patients by transient elastography (TE) - lack of interference by iron deposition.

2009

The correlation between liver stiffness, measured by transient elastography, liver fibrosis, using the histological METAVIR score, and iron overload, measured by atomic absorption spectrometry was evaluated in 56 homozygous-beta-thalassaemics. Liver stiffness increased proportionally to liver fibrosis staging (r = 0.70; P > 0.001) independently of liver iron concentration (r = 0.01; P = 0.932). The area under the receiver-operating characteristic curve for prediction of cirrhosis was 0.997 (95% confidence interval [CI]: 0.925-1.000) with cut-off of 13 kPa with 100% sensitivity (95% CI: 69.0-100.0) and 95% specificity (95% CI: 84.2-99.3). Transient elastography is a reliable non-invasive too…

AdultLiver CirrhosisMalemedicine.medical_specialtyLiver Iron ConcentrationCirrhosisIron OverloadBiopsyGastroenterologyYoung AdultInternal medicineBiopsymedicineHumansChildmedicine.diagnostic_testbusiness.industrybeta-ThalassemiaHematologyHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseConfidence intervalHemoglobinopathyLiverElasticity Imaging TechniquesFemaleTransient elastographyHepatic fibrosisbusinessEpidemiologic MethodsBritish journal of haematology
researchProduct

Entecavir effectiveness in naïve and NUC experienced patients: Interim analysis of the ENTAS cohort study of patients with chronic hepatitis B

2014

medicine.medical_specialtyHepatologyChronic hepatitisbusiness.industryInternal medicineGastroenterologymedicineEntecavirInterim analysisbusinessmedicine.drugCohort studyDigestive and Liver Disease
researchProduct

Is Transient Elastography Needed for Noninvasive Assessment of High-Risk Varices? The REAL Experience

2019

INTRODUCTION: The Baveno VI consensus guidelines and an expanded algorithm suggest that transient elastography (TE) and platelet (PLT) count can be used to identify patients with cirrhosis who can avoid esophagogastroduodenoscopy (EGD). The primary aims of this study were to assess the ability of a simple algorithm, which uses only laboratory parameters, to predict medium/large esophageal varices (EV) in patients with hepatitis C virus (HCV) and cirrhosis from the Rete Sicilia Selezione Terapia-HCV (RESIST-HCV) cohort and to compare the performance of the algorithm with Baveno VI and Expanded Baveno VI criteria. The secondary aim was to assess the role of TE in ruling out large EV. METHODS:…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisBAVENO VI CRITERIA PORTAL-HYPERTENSION CONSENSUS WORKSHOP LIVER STIFFNESS PLATELET COUNT CIRRHOSIS DIAGNOSIS;Esophageal and Gastric Varices03 medical and health sciences0302 clinical medicineRESIST-HCVmedicineesophageal varicesHumansBaveno VIEndoscopy Digestive SystemSerum AlbuminAgedHepatologymedicine.diagnostic_testPlatelet CountEsophagogastroduodenoscopybusiness.industryfungiGastroenterologyReproducibility of Resultsfood and beveragesHepatitis C ChronicMiddle Agedmedicine.diseasetransient elastographyEndoscopyLogistic ModelsCIRRHOSIS PORTAL HYPERTENSION VARICES STIFFNESS030220 oncology & carcinogenesistransient elastography esophageal varices HCV RESIST-HCV Baveno VIMultivariate AnalysisHCVElasticity Imaging TechniquesFemale030211 gastroenterology & hepatologyRadiologyGastrointestinal HemorrhagebusinessVaricesTransient elastographyAlgorithms
researchProduct

Cardiotoxicity mechanisms of the combination of BRAF-inhibitors and MEK-inhibitors.

2018

Many new drugs have appeared in last years in the oncological treatment scenario. Each drug carries an important set of adverse events, not less, cardiovascular adverse events. This aspect is even more important considering the increasing use of combination therapies with two drugs, or three drugs as in some ongoing clinical trials. Besides it represents a growing problem for Cardiologists, that face it in every day clinical practice and that will face it probably more and more in the coming years. This work reviews the mechanism of action of BRAF-inhibitors and MEK-inhibitors used together, the pathophysiological mechanisms that lead to cardiovascular toxicity. Particularly, it focuses on …

DrugCardiovascular toxicityBRAF inhibitorProto-Oncogene Proteins B-rafmedicine.medical_specialtyCombination therapySettore MED/06 - Oncologia Medicamedia_common.quotation_subjectDecreased ejection fraction030204 cardiovascular system & hematologyCardiovascular System03 medical and health sciences0302 clinical medicineCardiovascular toxicityAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansPharmacology (medical)Intensive care medicineAdverse effectBRAF inhibitor; Cardio-oncology; Cardiovascular toxicity; Decreased ejection fraction; Hypertension; MEK inhibitor; Pharmacology; Pharmacology (medical)MelanomaProtein Kinase Inhibitorsmedia_commonPharmacologyMitogen-Activated Protein Kinase KinasesCardiotoxicityMEK inhibitorClinical Trials as Topicbusiness.industryMEK inhibitorCancermedicine.diseaseCardiotoxicityClinical trialCardio-oncology030220 oncology & carcinogenesisHypertensionbusinessPharmacologytherapeutics
researchProduct

Noninvasive assessment of liver fibrosis in thalassaemia major patients by transient elastography (TE) - lack of interference by iron deposition.

2009

The correlation between liver stiffness, measured by transient elastography, liver fibrosis, using the histological METAVIR score, and iron overload, measured by atomic absorption spectrometry was evaluated in 56 homozygous-b-thalassaemics. Liver stiffness increased proportionally to liver fibrosis staging (r = 0Æ70; P > 0Æ001) independently of liver iron concentration (r = 0Æ01; P = 0Æ932). The area under the receiver-operating characteristic curve for prediction of cirrhosis was 0Æ997 (95% confidence interval [CI]: 0Æ925–1Æ000) with cut-off of 13 kPa with 100% sensitivity (95% CI: 69Æ0–100Æ0) and 95% specificity (95% CI: 84Æ2–99Æ3). Transient elastography is a reliable non-invasive tool f…

cirrhosis liver fibrosis liver iron concentration thalassaemia transient elastography
researchProduct

Targeted Therapies in Hepatocellular Carcinoma

2015

Hepatocellular carcinoma (HCC) is one of the main causes of death in patients affected by chronic liver diseases. The awareness of the biomolecular mechanisms underlying the complex carcinogenic process led to the development of targeted molecules, which are able to block this process. Sorafenib is a tyrosine-kinase inhibitor, and currently, it is the only drug approved by the US Food and Drug Administration (FDA) for the treatment of HCC. However, some studies have demonstrated the efficacy of single drug therapies or combination therapies. They showed an improvement with regard to overall survival, time to progression, and progression-free survival, although these therapies were not free …

DrugOncologySorafenibmedicine.medical_specialtyCirrhosisbusiness.industrymedia_common.quotation_subjectmedicine.medical_treatmentPharmacologymedicine.diseasedigestive system diseasesFood and drug administrationLiver diseaseInternal medicineHepatocellular carcinomamedicineIn patientbusinessAdjuvantmedia_commonmedicine.drug
researchProduct

Transient elastography vs. platelets or APRI score to assess fibrosis in chronic hepatitis C

2008

medicine.medical_specialtyHepatologyChronic hepatitisbusiness.industryFibrosisInternal medicineGastroenterologymedicinePlateletbusinessTransient elastographymedicine.diseaseGastroenterologyDigestive and Liver Disease
researchProduct

Fibrosis staging in chronic hepatitis C: Analysis of discordance between transient elastography and liver biopsy

2009

Summary.  In chronic hepatitis C, transient elastography (TE) accurately identifies cirrhosis, but its ability to assess significant fibrosis (Metavir ≥ F2) is variable. Constitutional and liver disease-related factors may influence TE and here we examined the variables associated with differences. Three hundred consecutive hepatitis C virus (HCV)-RNA positive patients had biochemical tests, TE and a biopsy performed on the same day. The Dale model was used to identify the variables associated with discordance between biopsy and elastography results. In 97 patients (34.2%), TE and histological assessment were discordant. Seventy-six of 286 (26.6%) had stage ≥F2 and TE < 7.1 kPa (false negat…

AdultLiver CirrhosisMalemedicine.medical_specialtyPathologyCirrhosisTransient elastographyHepatitis C virusBiopsyLiver fibrosismedicine.disease_causeGastroenterologySeverity of Illness IndexAminotranferases; Liver fibrosis; Transient elastography; Adult; Diagnostic Errors; Female; Hepatitis C Chronic; Histocytochemistry; Humans; Liver Cirrhosis; Male; Middle Aged; ROC Curve; Transaminases; Biopsy; Elasticity Imaging Techniques; Severity of Illness Index; Hepatology; Infectious Diseases; Virology; Medicine (all)Liver diseaseInternal medicineVirologyBiopsymedicineHumansDiagnostic ErrorsChronicAminotranferases liver fibrosis transient elastographyTransaminasesmedicine.diagnostic_testReceiver operating characteristicHepatologybusiness.industryHistocytochemistryMedicine (all)Hepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseHepatitis CInfectious DiseasesROC CurveLiver biopsyAminotranferasesElasticity Imaging TechniquesFemaleTransient elastographybusiness
researchProduct

Comparison of transient elastography and acoustic radiation force impulse for non-invasive staging of liver fibrosis in patients with chronic hepatit…

2011

Transient elastography (TE) is adequate for a diagnosis of cirrhosis, but its accuracy for milder stages of fibrosis is much less satisfactory. The objective of this study was to compare the performance and the discordance rate of acoustic radiation force impulse (ARFI) and TE with liver biopsy in a cohort of chronic hepatitis C (CHC) patients.One hundred thirty-nine consecutive patients with CHC were enrolled in two tertiary centers, and evaluated for histological (Metavir score) and biochemical features. All patients underwent TE and ARFI.TE was unreliable in nine patients (6.5%), while in no cases (0%) were ARFI invalid measurements recorded (P=0.029). By area under receiver operating ch…

AdultLiver CirrhosisMalemedicine.medical_specialtyHepacivirusLiver fibrosisBiopsyHepacivirusImpulse (physics)behavioral disciplines and activitiesCohort StudiesElasticity Imaging TechniquesBiopsyotorhinolaryngologic diseasesMedicineHumansProspective StudiesAcoustic radiation forceAgedHepatologybiologymedicine.diagnostic_testbusiness.industryarfi fibroscan hcv fibrosisGastroenterologyReproducibility of ResultsHepatitis CHepatitis C ChronicMiddle Agedbiology.organism_classificationmedicine.diseaseROC CurveElasticity Imaging TechniquesRNA ViralFemalesense organsRadiologyTransient elastographybusinesspsychological phenomena and processes
researchProduct

What links BRAF to the heart function? new insights from the cardiotoxicity of BRAF inhibitors in cancer treatment

2015

The RAS-related signalling cascade has a fundamental role in cell. It activates differentiation and survival. It is particularly important one of its molecules, B-RAF. B-RAF has been a central point for research, especially in melanoma. Indeed, it lacked effective therapeutic weapons since the early years of its study. Molecules targeting B-RAF have been developed. Nowadays, two classes of molecules are approved by FDA. Multi-target molecules, such as Sorafenib and Regorafenib, and selective molecules, such as Vemurafenib and Dabrafenib. Many other molecules are still under investigation. Most of them are studied in phase 1 trials. Clinical studies correlate B-RAF inhibitors and QT prolonga…

SorafenibProto-Oncogene Proteins B-rafB-RAF inhibitorscardio-oncologySkin NeoplasmscardiotoxicityAntineoplastic AgentsReviewB-RAF inhibitorPharmacologyQT intervalSudden cardiac deathchemistry.chemical_compoundRegorafenibmedicineAnimalsHumansMolecular Targeted TherapydabrafenibVemurafenibMelanomaProtein Kinase InhibitorsCardiotoxicityClinical Trials as Topicbusiness.industryMelanomaB-RAFDabrafenibArrhythmias CardiacHeartmedicine.diseaseOncologychemistryCancer researchbusinessmedicine.drugSignal TransductionOncotarget
researchProduct

Modified spleen stiffness measurement by transient elastography is associated with presence of large oesophageal varices in patients with compensated…

2013

To evaluate the accuracy of liver transient elastography (TE), spleen TE and other noninvasive tests (AAR, APRI score, platelet count, platelet/spleen ratio) in predicting the presence and the size of oesophageal varices in compensated hepatitis C virus (HCV) cirrhosis, we studied 112 consecutive patients with compensated HCV cirrhosis who underwent biochemical tests, gastrointestinal endoscopy, liver TE and spleen TE by Fibroscan(®) (Echosens, Paris, France) using a modified software version with a range between 1.5 and 150 kPa. Spleen TE was not reliable in 16 patients (14.3%). Among the 96 patients with a valid measurement (69.8% men, mean age: 63.2 ± 9.5 years), 43.7% had no oesophageal…

AdultLiver CirrhosisMalemedicine.medical_specialtyCirrhosisHepatitis C virusSpleenmedicine.disease_causeEsophageal and Gastric VaricesGastroenterologySensitivity and SpecificityVaricose VeinsVirologyInternal medicinemedicineHumansProspective StudiesAgedUnivariate analysisHepatologybusiness.industrycirrhosisHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseaseFibrosisInfectious Diseasesmedicine.anatomical_structureROC CurvePortal hypertensionElasticity Imaging TechniquesFemaleVaricesTransient elastographybusinessBiomarkersSpleen
researchProduct

Dual therapy with peg-interferon and ribavirin in thalassemia major patients with chronic HCV infection: Is there still an indication?

2016

Background: Iron overload and hepatitis C virus (HCV) infection together can lead to chronic liver damage in thalassemia major (TM) patients. Aims: We investigated viral, genetic, and disease factors influencing sustained virological response (SVR) after peg-interferon and ribavirin therapy in TM patients with HCV infection. Methods: We analyzed 230 TM patients with HCV infection (mean age 36.0 ± 6.3 years; 59.1% genotype 1; 32.2% genotype 2; 3.4% genotype 3; and 5.3% genotype 4; 28.7% carried CC allele of rs12979860 in IL28B locus; 79.6% had chronic hepatitis and 20.4% cirrhosis; 63.5% naive and 36.5% previously treated with interferon alone) treated in 14 Italian centers. Results: By mul…

Liver Cirrhosis0301 basic medicineMaleCirrhosisThalassemiaHepacivirusCirrhosis; Hepatitis C virus; IL28B polymorphisms; Iron liver overload; Peg-interferon; Ribavirin; Sustained virological response; Thalassemia major; Adult; Antiviral Agents; Drug Therapy Combination; Female; Heart Diseases; Hepacivirus; Hepatitis C Chronic; Humans; Interferon-alpha; Interleukins; Italy; Liver Cirrhosis; Logistic Models; Male; Multivariate Analysis; Polymorphism Single Nucleotide; Retrospective Studies; Ribavirin; Treatment Outcome; Viral Load; beta-Thalassemiamedicine.disease_causeGastroenterologychemistry.chemical_compound0302 clinical medicineRetrospective StudieThalassemia majorMultivariate AnalysiGastroenterologyBeta thalassemiaHepatitis CViral LoadSustained virological responseHeart DiseaseTreatment OutcomeItaly030211 gastroenterology & hepatologyDrug Therapy CombinationFemaleViral loadHumanAdultmedicine.medical_specialtyHeart DiseasesLogistic ModelHepatitis C virusLiver CirrhosiAlpha interferonIL28B polymorphismAntiviral AgentsPolymorphism Single Nucleotide03 medical and health sciencesIron liver overloadInternal medicineRibavirinmedicineHumansRetrospective StudiesAntiviral AgentCirrhosiHepaciviruPeg-interferonHepatologybusiness.industryInterleukinsRibavirinbeta-ThalassemiaInterferon-alphaHepatitis C ChronicInterleukinmedicine.diseaseLogistic Models030104 developmental biologychemistryMultivariate AnalysisImmunologyInterferonsbusinessHepatitis C viru
researchProduct

Refining the Baveno VI elastography criteria for the definition of compensated advanced chronic liver disease

2021

Background: The Baveno VI consensus proposed a dual liver stiffness (LS) by transient elastography threshold of &lt;10 and &gt;15 kPa for excluding and diagnosing compensated advanced chronic liver disease (cACLD) in the absence of other clinical signs. Herein, we aimed to validate these criteria in a real-world multicentre study. Methods: We included 5,648 patients (mean age 51 ± 13 years, 53% males) from 10 European liver centres who had a liver biopsy and LS measurement within 6 months. We included patients with chronic hepatitis C (n = 2,913, 52%), non-alcoholic fatty liver disease (NAFLD, n = 1,073, 19%), alcohol-related liver disease (ALD, n = 946, 17%) or chronic hepatitis B (n = 716…

0301 basic medicineAlcoholic liver diseasemedicine.medical_specialtyCirrhosis[SDV]Life Sciences [q-bio]Chronic liver diseaseAsymptomaticGastroenterology03 medical and health sciencesLiver disease0302 clinical medicineInternal medicineNAFLDmedicineViral hepatitis10. No inequalityPortal hypertensionComputingMilieux_MISCELLANEOUSCirrhosiHepatologymedicine.diagnostic_testbusiness.industryFatty liverAlcoholic liver diseasemedicine.disease3. Good health030104 developmental biologyFibroscanCirrhosisLiver biopsyFIB-4030211 gastroenterology & hepatologymedicine.symptomTransient elastographybusinessViral hepatitis.
researchProduct

Error factors for transient elastography in chronic hepatitis C

2008

medicine.medical_specialtyHepatologyChronic hepatitisbusiness.industryInternal medicineGastroenterologymedicineTransient elastographybusinessGastroenterologyDigestive and Liver Disease
researchProduct

High rate of misclassification of fibrosis stage using transient elastography thresholds to prioritize HCV patients for antiviral treatment

2017

High rateOncologyPathologymedicine.medical_specialtyHepatologybusiness.industryInternal medicineGastroenterologymedicineFibrosis stageAntiviral treatmentTransient elastographybusinessDigestive and Liver Disease
researchProduct

Targeted Therapies in Hepatocellular Carcinoma

2014

Abstract: The onset of hepatocellular carcinoma (HCC) is related to the development of non-neoplastic liver disease, such as viral infections and cirrhosis. Even though patients with chronic liver diseases undergo clinical surveillance for early diagnosis of HCC, this cancer is often diagnosed in advanced stage. In this case locoregional treatment is not possible and systemic therapies are the best way to control it. Until now sorafenib, a Raf and multi-kinase inhibitor has been the best, choice to treat HCC systemically. It showed a survival benefit in multicenter phase III trials. However the proper patient setting to treat is not well defined, since the results in Child-Pugh B patients a…

NiacinamideVascular Endothelial Growth Factor ACarcinoma HepatocellularSettore MED/06 - Oncologia MedicaCirrhosis hepatocellular carcinoma liver disease targeted therapiesAntineoplastic AgentsBiochemistryDrug DiscoveryAnimalsHumansMolecular Targeted TherapyBiologyProtein Kinase InhibitorsPharmacologyPharmacology. TherapyPhenylurea CompoundsTOR Serine-Threonine KinasesLiver NeoplasmsOrganic ChemistryAntibodies MonoclonalSorafenibdigestive system diseasesErbB ReceptorsChemistryLiverMolecular MedicineCurrent Medicinal Chemistry
researchProduct

The risk of hepatocellular carcinoma in HBV cirrhosis is affected by polymorphisms of the MERTK gene

2014

MERTK GeneCirrhosisHepatologybusiness.industryHepatocellular carcinomaGastroenterologyCancer researchMedicineHCC HBV MERTK Gene Polymorphismsbusinessmedicine.diseaseDigestive and Liver Disease
researchProduct

Quantification of fibrosis by collagen proportionate area predicts hepatic decompensation in hepatitis C cirrhosis.

2015

SummaryBackground It is unclear whether the course of cirrhosis and its prognosis are related to the amount of collagen in the liver. Aim To determine whether fibrosis, assessed by collagen proportionate area (CPA) in patients with compensated cirrhosis, is associated with the presence of oesophageal varices, and predict disease decompensation during the follow-up period. Methods We prospectively evaluated 118 consecutive patients with compensated cirrhosis to correlate fibrosis, assessed by CPA in liver biopsies, with the presence of oesophageal varices (OV) and with the rate of liver decompensation (LD) development during a median follow-up of 72 months. Results At baseline 38 (32.2%) pat…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisBiopsyEsophageal and Gastric VaricesGastroenterologySeverity of Illness IndexSex FactorsFibrosisInternal medicineHypertension PortalmedicineHumansPharmacology (medical)DecompensationProspective StudiesAgedHepatologyReceiver operating characteristicbusiness.industryProportional hazards modelGastroenterologyAge FactorsHepatitis CHepatitis C ChronicMiddle Agedmedicine.diseasePrognosisFibrosisCPAROC CurvePortal hypertensionFemaleCollagenbusinessVaricesLiver FailureAlimentary pharmacologytherapeutics
researchProduct

Insulin resistance is a risk factor for esophageal varices in hepatitis C virus cirrhosis

2008

Indirect methods to predict the presence of esophageal varices (EV) in patients with cirrhosis are not sensitive enough to be used as a surrogate for endoscopy. We tested the effectiveness of liver stiffness measurement (LSM) by transient elastography and the presence of insulin resistance (IR), a marker associated with fibrosis progression, in the noninvasive prediction of portal hypertension. One hundred four consecutive patients with newly diagnosed Child A hepatitis C virus (HCV) cirrhosis underwent upper gastrointestinal endoscopy to search for EV. Clinical, anthropometric, biochemical, ultrasonographic, and metabolic features, including IR by the homeostasis model assessment (HOMA), a…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisEsophageal and Gastric VaricesGastroenterologyEsophageal varicesInsulin resistanceRisk FactorsDiabetes mellitusInternal medicineHypertension PortalmedicineHumansEndoscopy Digestive SystemProspective StudiesAgedHepatologyPlatelet Countbusiness.industryHepatitis CMiddle AgedHepatologymedicine.diseaseHepatitis CLiverROC CurveMultivariate AnalysisDisease ProgressionElasticity Imaging TechniquesPortal hypertensionFemaleInsulin ResistanceTransient elastographybusinessSpleenHepatology
researchProduct

Naïve hepatitis B e antigen-negative chronic hepatitis B patients are at risk of carotid atherosclerosis: A prospective study

2021

BACKGROUND There is an increased risk of atherosclerosis in patients with chronic hepatitis C or human immunodeficiency virus, but there is scarce data on hepatitis B virus infection. The hypothesis of this study is that hepatitis B virus infection increases the risk of carotid plaques and subclinical atherosclerosis in naïve hepatitis B e antigen (HBeAg) negative subjects. AIM To assess the rate of carotid plaques and subclinical atherosclerosis in naïve HBeAg negative subjects in comparison with a cohort of healthy controls. METHODS Prospective case-control collaborative study conducted in two tertiary hospitals. Four hundred and two subjects prospectively recruited at the outpatient clin…

Carotid Artery DiseasesHepatitis B virusmedicine.medical_specialtyIntima-media thicknessCardiovascular risk Carotid plaques Endothelial dysfunction Hepatitis B virus Intima-media thickness Subclinical atherosclerosis Carotid Intima-Media Thickness Hepatitis B e Antigens Humans Prospective Studies Carotid Artery Diseases Hepatitis B Chronicmedicine.disease_causeCarotid Intima-Media ThicknessGastroenterologyHepatitis B ChronicInternal medicinemedicineHumansOutpatient clinicCarotid plaquesSubclinical atherosclerosisEndothelial dysfunctionHepatitis B e AntigensProspective StudiesRisk factorProspective cohort studyHepatitis B virusbusiness.industryGastroenterologyGeneral MedicineOdds ratioHepatitis BCardiovascular riskmedicine.diseaseIntima-media thicknessHBeAgProspective StudybusinessWorld Journal of Gastroenterology
researchProduct

Phylogenetic analysis in the clinical risk management of an outbreak of hepatitis C virus infection among transfused thalassaemia patients in Italy

2021

Background: Occurrence of hepatitis C virus (HCV) infection is reduced by effective risk management procedures, but patient-to-patient transmission continues to be reported in healthcare settings. Aim: To report the use of phylogenetic analysis in the clinical risk management of an HCV outbreak among 128 thalassaemia outpatients followed at a thalassaemia centre of an Italian hospital. Methods: Epidemiological investigation and root-cause analysis were performed. All patients with acute hepatitis and known chronic infection were tested for HCV RNA, HCV genotyping, and NS3, NS5A, and NS5B HCV genomic region sequencing. To identify transmission clusters, phylogenetic trees were built for each…

SofosbuvirClinical risk management Hepatitis C virus (HCV) Molecular epidemiology Nosocomial outbreak Phylogenetic analysis Antiviral Agents Bayes Theorem Disease Outbreaks Genotype Hepacivirus Humans Italy Phylogeny Risk Management Hepatitis C ThalassemiaHepacivirusHepacivirus030501 epidemiologySettore MED/42 - Igiene Generale E Applicatamedicine.disease_causeDisease OutbreaksSettore MED/07chemistry.chemical_compoundSettore BIO/13 - Biologia ApplicataEpidemiologyMedicinePhylogenySettore MED/12 - Gastroenterologia0303 health sciencesClinical risk managementPhylogenetic analysisbiologyTransmission (medicine)virus diseasesGeneral MedicineHepatitis CHepatitis C virus (HCV)Hepatitis CInfectious DiseasesItalyMolecular epidemiologyThalassemia0305 other medical sciencemedicine.drugMicrobiology (medical)Ledipasvirmedicine.medical_specialtyGenotypeHepatitis C virusAntiviral Agents03 medical and health sciencesPhylogenetic analysiInternal medicineHumansRisk Management030306 microbiologybusiness.industryNosocomial outbreakBayes Theorembiology.organism_classificationmedicine.diseasedigestive system diseasesChronic infectionchemistrybusiness
researchProduct

Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C.

2012

BACKGROUND AND AIMS: Randomized controlled trials (RCTs) show that triple therapy (TT) with peginterferon alfa, ribavirin and boceprevir (BOC) or telaprevir (TVR) is more effective than peginterferon-ribavirin dual therapy (DT) in the treatment of previously untreated patients with genotype 1 (G1) chronic hepatitis C (CHC). We assess the cost-effectiveness of TT compared to DT in the treatment of untreated patients with G1 CHC. METHODS: We created a Markov Decision Model to evaluate, in an untreated Caucasian patients aged 50 years, weight 70 kg, with G1 CHC and Metavir F2 liver fibrosis score, for a time horizon of twenty years, the cost-effectiveness of the following 5 competing strategie…

MaleSettore MED/12 - GastroenterologiaHepatologyGenotypeProlineCost-Benefit AnalysisSettore MED/09 - MEDICINA INTERNAHepatitis C ChronicMiddle AgedHepatitis Cboceprevirchronic hepatitis CHumanstelaprevirCOST-EFFECTIVENESS OF HCV PROTEASE INHIBITORSSettore SECS-S/05 - Statistica SocialeSettore SECS-S/01 - StatisticaOligopeptidesHepatology (Baltimore, Md.)
researchProduct

Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: A meta-analysis

2009

Efficacy of retreatment with pegylated interferon (PEG-IFN) plus ribavirin of non-responders to standard or pegylated IFN plus ribavirin has been assessed in various studies, but sustained virologic response (SVR) rates are variable and factors influencing efficacy and tolerability still remain incompletely defined. We aimed to focus on SVR rates and to identify factors influencing them in this meta-analysis.MEDLINE as well as a manual search were used. Studies were included if they were controlled or uncontrolled trials, if they had been published as full-length papers and if they included non-responders to standard or pegylated IFN and ribavirin therapy. Fourteen trials were included in t…

medicine.medical_specialtyGenotypeHepatitis C virusHepacivirusmedicine.disease_causeAntiviral AgentsPolyethylene Glycolschemistry.chemical_compoundPharmacotherapyPegylated interferonInternal medicineRibavirinmedicineHumansHepatologybusiness.industryRibavirinvirus diseasesHepatitis CHepatitis C Chronicmedicine.diseaseRecombinant Proteinsdigestive system diseasesConfidence intervalTolerabilitychemistryMeta-analysisInterferon Type IImmunologyDrug Therapy Combinationbusinessmedicine.drugJournal of Hepatology
researchProduct

HBsAg quantification in HBeAg negative cirrhosis on nucleoside/nucleotide analogue (NA) and risk of development of HCC

2013

HBsAg-quantification HBeAg-negative cirrhosis therapy
researchProduct

GENETIC, VIROLOGICAL AND CLINICAL FACTORS ASSOCIATED WITH HEPATOCELLULAR CARCINOMA DEVELOPEMENT IN PATIENTS WITH CHRONIC HBV AND HCV INFECTION

HCV cirrhosiSettore MED/12 - GastroenterologiaMERTK geneqHBsAg level serumchronic HBV infectionchronic HCV infectiongenetic factorclinical factors HBV cirrhosihepatocellular carcinomavirological factorchronic HBV infection; chronic HCV infection; hepatocellular carcinoma; genetic factors; virological factor; clinical factors HBV cirrhosis; HCV cirrhosis; MERTK gene; qHBsAg level serum
researchProduct

Comparison of Histochemical Stainings in Evaluation of Liver Fibrosis and Correlation with Transient Elastography in Chronic Hepatitis.

2015

Background and Aim. The best staining to evaluate liver fibrosis in liver hepatitis is still a debated topic. This study aimed to compare Masson’s trichrome (MT), Sirius Red (SR), and orcein stainings in evaluating liver fibrosis in chronic HCV hepatitis (CHC) with semiquantitative and quantitative methods (Collagen Proportionate Area (CPA) by Digital Image Analysis (DIA)) and correlate them with transient elastography (TE).Methods. Liver stiffness evaluation of 111 consecutive patients with CHC was performed by TE. Semiquantitative staging by Metavir score system and CPA by DIA were assessed on liver biopsy stained with MT, SR, and orcein.Results. MT, SR, and orcein staining showed concord…

AdultLiver CirrhosisMaleCancer ResearchPathologymedicine.medical_specialtyArticle SubjectAdolescentliver fibrosis elastography Digital Image Analysis liver biopsySettore MED/08 - Anatomia PatologicaPathology and Forensic Medicinechemistry.chemical_compoundYoung AdultTrichromeFibrosisImage Processing Computer-AssistedMedicineHumansOrceinSirius RedRC254-282AgedHepatitis ChronicHepatitisSettore MED/12 - Gastroenterologiamedicine.diagnostic_testQH573-671Staining and Labelingbusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensCell BiologyGeneral MedicineMiddle Agedmedicine.diseaseStainingchemistryLiver biopsyMolecular MedicineElasticity Imaging TechniquesFemalebusinessTransient elastographyCytologyResearch ArticleAnalytical cellular pathology (Amsterdam)
researchProduct

Quantification of fibrosis in chronic hepatitis C: Performance of Transient Elastography and Acoustic Radiation Force Impulse using Collagen Proporti…

2014

medicine.medical_specialtyHepatologyChronic hepatitisbusiness.industryFibrosisGastroenterologyMedicineRadiologyImpulse (physics)businessTransient elastographymedicine.diseaseAcoustic radiation forceDigestive and Liver Disease
researchProduct

Conquests and perspectives of cardio-oncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy

2015

Abstract: Introduction: Angiogenesis is fundamental for tumor development and progression. Hence, anti-angiogenic drugs have been developed to target VEGF and its receptors (VEGFRs). Several tyrosine kinase inhibitors (TKIs) have been developed over the years and others are still under investigation, each anti-VEGFR TKI showing a different cardiotoxic profile. Knowledge of the cardiac side-effects of each drug and the magnitude of their expression and frequency can lead to a specific approach. Areas covered: This work reviews the mechanism of action of anti-VEGFR TKIs and the pathophysiological mechanisms leading to cardiotoxicity, followed by close examination of the most important drugs i…

SorafenibOncologymedicine.medical_specialtymedicine.drug_classSettore MED/06 - Oncologia MedicaAntineoplastic AgentsPharmacologyVandetanibModels BiologicalTyrosine-kinase inhibitorPazopanibchemistry.chemical_compoundInternal medicineRegorafenibNeoplasmsmedicineHumansPharmacology (medical)Molecular Targeted TherapyProtein Kinase Inhibitorstyrosine kinase inhibitor cardiac toxicityNeovascularization PathologicSunitinibbusiness.industryPharmacology. TherapyCancerHeartGeneral MedicineDrugs InvestigationalProtein-Tyrosine Kinasesmedicine.diseaseAxitinibReceptors Vascular Endothelial Growth FactorchemistryCardiovascular Diseasesbusinessmedicine.drug
researchProduct

Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir

2019

Background and Aims: Tenofovir disoproxil fumarate (TDF) is recommended for chronic hepatitis B (CHB) treatment, but it may induce kidney dysfunction whose management is not yet known. This Italian, multicentre, retrospective study aimed to assess the efficacy and safety of switching to entecavir (ETV) patients who developed TDF-associated glomerular and/or tubular dysfunction. Methods: A total of 103 TDF-treated patients were included as follows: age 64 years, 83% male, 49% cirrhotics, 98% with undetectable HBV DNA, 47% with previous lamivudine resistance (LMV-R) and 71% previously treated with adefovir. Twenty-nine (28%) were switched to ETV because estimated glomerular filtration rate (e…

MaleTime FactorsSustained Virologic Responsehepatitis B viruKidneyGastroenterologyhepatitis B virus; liver; liver function tests; renal dysfunction; viral hepatitischemistry.chemical_compound0302 clinical medicine80 and overAdefovirChronicAged 80 and overKidneymedicine.diagnostic_testDrug Substitutionhepatitis B virus; liver; liver function tests; renal dysfunction; viral hepatitis; HepatologyEntecavirMiddle AgedHepatitis BHepatitis BTreatment Outcomemedicine.anatomical_structureItaly030220 oncology & carcinogenesisFemaleKidney Diseases030211 gastroenterology & hepatologyViral hepatitismedicine.drugAdultmedicine.medical_specialtyGuaninehepatitis B virus; liver; liver function tests; renal dysfunction; viral hepatitis; Adult; Aged; Aged 80 and over; Antiviral Agents; Female; Guanine; Hepatitis B Chronic; Humans; Italy; Kidney; Kidney Diseases; Male; Middle Aged; Recovery of Function; Retrospective Studies; Sustained Virologic Response; Tenofovir; Time Factors; Treatment Outcome; Drug Substitutionviral hepatitisRenal functionliverAntiviral Agents03 medical and health sciencesHepatitis B ChronicInternal medicinerenal dysfunctionmedicineHumansliver function testTenofovirAgedRetrospective StudiesCreatinineHepatologybusiness.industryviral hepatitiRecovery of Functionmedicine.diseasechemistryliver function testsbusinessLiver function testshepatitis B virus
researchProduct

NS5A gene analysis by next generation sequencing in HCV nosocomial transmission clusters of HCV genotype 1b infected patients

2019

Background: The aim of the study was to investigate the intra-host variability through next-generation-sequencing (NGS) of the NS5A-gene in nosocomial transmission-clusters observed in two Italian hospitals among hepatitis C virus (HCV)-genotype-1b infected patients. Methods: HCV-sequencing was performed by Sanger-sequencing (NS3 + NS5A + NS5B) and by NGS (NS5A, MiSeq-Illumina) in 15 HCV-1b infected patients [five acute with onco-hematologic-disease and 10 (4/6 acute/chronic) with &beta

Male0301 basic medicinevirusesDrug ResistanceHepacivirusViral Nonstructural Proteinsmedicine.disease_causeSettore MED/42 - Igiene Generale E ApplicataGastroenterologySettore MED/07chemistry.chemical_compound0302 clinical medicineGenotype 1bMedicineVirallcsh:QH301-705.5PhylogenyCross Infectionnosocomial transmissionGastroenterologyHigh-Throughput Nucleotide Sequencingvirus diseasesHCV; NGS; acute infection; chronic infection; nosocomial transmission; sequencing; Acute Disease; Adult; Amino Acid Substitution; Antiviral Agents; Blood Transfusion; Chronic Disease; Cross Infection; Drug Resistance Viral; Female; Genotype; Hepacivirus; Hepatitis C; High-Throughput Nucleotide Sequencing; Host-Pathogen Interactions; Humans; Interferons; Male; Middle Aged; Phylogeny; Polymorphism Single Nucleotide; Viral Nonstructural Proteins; beta-ThalassemiaSingle NucleotideGeneral MedicinesequencingMiddle AgedHepatitis CNGSAcute DiseaseHost-Pathogen InteractionsHCVFemale030211 gastroenterology & hepatologyAdultmedicine.medical_specialtyGenotypeHepatitis C virusViral quasispeciesPolymorphism Single NucleotideAntiviral AgentsArticleDNA sequencing03 medical and health sciencesInternal medicineDrug Resistance ViralHumansBlood TransfusionPolymorphismNS5ANS5BGeneHepatologybusiness.industryNosocomial transmissionbeta-Thalassemiabiochemical phenomena metabolism and nutritionchronic infectionVirologydigestive system diseasesChronic infection030104 developmental biologyAmino Acid Substitutionchemistrylcsh:Biology (General)Chronic DiseaseHCV; NGS; acute infection; chronic infection; nosocomial transmission; sequencingInterferonsbusinessacute infectionDigestive and Liver Disease
researchProduct

STAGING OF FIBROSIS BY LIVER STIFFNESS MEASUREMENT IN THALASSEMICS WITH IRON OVERLOAD

2007

n
researchProduct

Fibrospleen: Measuring spleen stiffness by transient elastography increases accuracy of staging of liver fibrosis and of portal hypertension in chron…

2009

Pathologymedicine.medical_specialtyHepatologybusiness.industryLiver fibrosisGastroenterologySpleenmedicine.diseasemedicine.anatomical_structuremedicinePortal hypertensionViral hepatitisTransient elastographybusinessDigestive and Liver Disease
researchProduct

The Italian ENTAS cohort study: Entecavir effectiveness in naïve and treatment experienced patients with chronic hepatitis B

2015

medicine.medical_specialtyHepatologyChronic hepatitisbusiness.industryInternal medicineGastroenterologyMedicineEntecavirbusinessTreatment experiencedmedicine.drugCohort studyDigestive and Liver Disease
researchProduct

HCV Clearance Among Hemophiliacs and Beta-Thalassemics

2007

Hepatologybusiness.industryImmunologyGastroenterologyHcv clearanceMedicinenBeta (finance)businessGastroenterology
researchProduct

Non-invasive assessment of the liver fibrosis by transient elastography (TE) in patients with transfusion-dependent thalassemia

2008

medicine.medical_specialtyHepatologybusiness.industryInternal medicineLiver fibrosisNon invasiveGastroenterologymedicineTransfusion dependent thalassemiaIn patientbusinessTransient elastographyGastroenterologyDigestive and Liver Disease
researchProduct